A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Thirona Raises €7,5 Million New Financing to Accelerate the Adoption of its Breakthrough Innovations for Precision Medicine

What To Know

  • With the support of the investors, we are well geared to have our technology make a significant impact on patient care and the medical industry.
  • “The future of healthcare is undergoing a transformation, and we are at the forefront of this evolution, leading the way in our field.

Thirona, a global company specialized in advanced analysis of thoracic CT images with artificial intelligence, is thrilled to announce the successful completion of its new investment. The Company has secured €7,5 Million ($8 Million) of financing through a €5 Million investment round from HERAN Partners and Borski Fund, and a €2,5 Million grant from European Innovation Council (EIC).

Thirona is at the forefront of revolutionizing medical treatment and intervention pathways for lung diseases through cutting-edge artificial intelligence technologies, ultimately improving patient care and outcomes. The Company’s advanced capabilities in pre-operative and intra-operative imaging have the potential to significantly enhance the precision, accuracy, and efficiency of (robotic) bronchoscopic and surgical lung interventions, enabling easier-to-perform and less invasive procedures. Demonstrating consistently high performance across a wide range of diseases and pathologies, Thirona’s LungQ™ platform powers also a growing number of imaging-based exploratory research studies and clinical trials for development of novel pharmaceutical drugs. Having surpassed a total number of 15 million images analyzed, the Company evolved to a technologically mature, globally recognized expert in advaced image analysis.

With this financing, Thirona plans to accelerate the adoption of its break-through innovations for precision medicine.

“We are very pleased with the confidence our investors have shown in our vision and capabilities,” said Eva van Rikxoort, Founder and CEO of Thirona. “This funding will enable us to continue pushing the boundaries of AI-powered imaging and help advance personalized treatment for lung patients around the world.”

Katleen Vandersmissen from HERAN Partners, one of the key investors of this round, expressed enthusiasm about the company’s potential impact, stating, “Thirona has demonstrated exceptional promise in the field of medical imaging. We are excited to support their mission to revolutionize healthcare through AI technology.”

According to Simone Brummelhuis from Borski Found, the latest investment will provide the company with the resources to expand its market presence. As Brummelhuis said, “Thirona has achieved major growth milestones, forged co-innovation partnerships with leading medical companies, and became leader in the MedTech space for lung image analysis.”

Rita Priori, Chief Technology Officer at Thirona, concludes: “The future of healthcare is undergoing a transformation, and we are at the forefront of this evolution, leading the way in our field. With the support of the investors, we are well geared to have our technology make a significant impact on patient care and the medical industry.”

SourceThirona
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.
SABIC advises the project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium.

By using this website you agree to accept Medical Device News Magazine Privacy Policy